Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Ovarian Neoplasms 57Carcinoma, Ovarian Epithelial 28Fallopian Tube Neoplasms 20Uterine Cervical Neoplasms 17Endometrial Neoplasms 17Breast Neoplasms 13Stomach Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Lung Neoplasms 9Prostatic Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Parkinson Disease 4, Autosomal Dominant Lewy Body 7Esophageal Neoplasms 7Carcinoma, Renal Cell 7Peritoneal Neoplasms 6Melanoma 6Uterine Neoplasms 4Urinary Bladder Neoplasms 4Small Cell Lung Carcinoma 4Sarcoma 4Pancreatic Neoplasms 4Neoplasms 4Head and Neck Neoplasms 4Esthesioneuroblastoma, Olfactory 4Colorectal Neoplasms 4Carcinoma, Transitional Cell 4Triple Negative Breast Neoplasms 3Salivary Gland Neoplasms 3Kidney Neoplasms 3Brenner Tumor 3

Interventions

pembrolizumab 3lenvatinib 2Injections 2anlotinib 1Paclitaxel 1NVP-BKM120 1Gemcitabine 1Doxorubicin 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Endometrial Cancer × Docetaxel × Gynecologic × Clear all
NCT05481645 2026-01-09

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
71 enrolled
GynecologicSarcoma

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡